Clinical trial
Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT]
NCT00400907 is registered in ClinicalTrials.gov with German High-Grade Non-Hodgkin's Lymphoma Study Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT]
- Lead sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- January 31, 2006
- Completion date
- Not reported
- Enrollment
- 667 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
long-term effects secondary to cancer therapy in adults, lymphoma